Abstract
Methods Based on in-vitro neutralizing activity in serum, patients (n=6, subtype A and B infected) were selected and Env sequences of early HIV-1 variants, still sensitive to autologous neutralization, were used to generate soluble Env as immunogens. Gp140 trimeric proteins were expressed (293T cells) and purified. Rabbits (4/group) were immunized s.c. at weeks 0, 2, 4, 8 with 100μg trimer adjuvanted with cationic CAF01. Control groups received 20μg and 100μg trimer plus/minus CAF01 respectively. Sera collected at weeks 0, 2, 4, 8, 12 and 14 were screened in gp120-IIIB ELISA and IgG was analyzed in the TZMbl neutralization assay.
Highlights
Eliciting broad cross neutralizing antibodies remains the primary and most challenging goal in HIV1 vaccine development
Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization
IgG titers measured 4 weeks after the last immunization clearly differed between groups (n=5) receiving 100μg/immunization (Geometric mean titer (GMT) : 152.601) and the group receiving 20μg/immunization (GMT : 13.262) or the group omitting CAF01 (GMT : 27.262)
Summary
Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization. L Heyndrickx1*, G Stewart-Jones, H Schuitemaker, E Bowles, L Buonaguro, M Jansson, B Grevstad, L Vinner, M Ramaswamy, P Biswas, G Scarlatti, G Vanham, A Fomsgaard
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
